Wiener klinische Wochenschrift

, Volume 130, Issue 5–6, pp 211–219 | Cite as

Initial Slovenian experience with MitraClip therapy

Careful selection of patients is crucial for optimal outcome
  • Jana Ambrožič
  • Marta Cvijič
  • Mojca Bervar
  • Špela Mušič
  • Matjaž Bunc
original article
  • 51 Downloads

Summary

Background

MitraClip is a percutaneous mitral repair technology increasingly used for high surgical risk patients with primary or secondary mitral regurgitation. We describe initial Slovenian experience with MitraClip and discuss the importance of identifying the suitable candidates for this procedure.

Methods

We retrospectively analyzed the first 10 patients (mean age 75.6 ± 6.9 years, logistic Euroscore 28.4 ± 10.9%) with severe and moderate to severe mitral regurgitation (8 secondary, 1 primary and 1 mixed etiology) who underwent a MitraClip procedure between January 2015 and February 2017.

Results

Acute reduction of mitral regurgitation was achieved in all but one patient (90%). There were no periprocedural mortalities and at short to mid-term follow-up (median 12 months, interquartile range 3–15 months). In eight patients improvement of functional class was observed at discharge. No functional improvement was achieved in a patient with advanced ischemic cardiomyopathy, and in a patient with degenerative mitral disease in whom the MitraClip procedure had failed necessitating mitral valve surgery. One patient experienced late leaflet detachment and was effectively managed with a second MitraClip procedure. There were two vascular complications at the access site and one percutaneous closure of an iatrogenic atrial septal defect.

Conclusion

Our initial experiences with a small number of patients indicate that percutaneous mitral repair with MitraClip is a feasible and safe method in high-risk patients. Special attention should be paid to careful patient selection including detailed echocardiographic evaluation of mitral valve anatomy, technical performance and final result, particularly at the beginning of the learning curve in order to reduce the rate of serious complications.

Keywords

MitraClip Mitral regurgitation Percutaneous mitral valve repair Echocardiography Mitral anatomy 

Notes

Compliance with ethical guidelines

Conflict of interest

J. Ambrožič, M. Cvijič, M. Bervar, Š. Mušič, and M. Bunc declare that they have no competing interests.

Ethical standards

This article does not contain any studies with human participants or animals performed by any of the authors. Informed consent was obtained from all patients identifiable from images or other information within the manuscript.

References

  1. 1.
    Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sarano M. Burden of valvular heart diseases: a population-based study. Lancet. 2006;368(9540):1005–11.CrossRefPubMedGoogle Scholar
  2. 2.
    ESC Scientific Document Group, Baumgartner H, Falk V, Bax JJ, et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2017;38(36):2739–91.Google Scholar
  3. 3.
    Scientific Document Committee of the European Association of Cardiovascular Imaging, Lancellotti P, Tribouilloy C, Hagendorff A, et al. Recommendations for the echocardiographic assessment of native valvular regurgitation: an executive summary from the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2013;14:611–44.CrossRefGoogle Scholar
  4. 4.
    Feldman T, Kar S, Rinaldi M, et al. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol. 2009;54(8):686–94.CrossRefPubMedGoogle Scholar
  5. 5.
    EVEREST II Investigators, Mauri L, Foster E, Glower DD, et al. 4‑year results of a randomized controlled trial of percutaneous repair versus surgery for mitral regurgitation. J Am Coll Cardiol. 2013;62(4):317–28.CrossRefGoogle Scholar
  6. 6.
    Maisano F, Franzen O, Baldus S, et al. Percutaneous mitral valve interventions in the real world: early and 1‑year results from the ACCESS-EU, a prospective, multicenter, nonrandomized post-approval study of the MitraClip therapy in Europe. J Am Coll Cardiol. 2013;62(12):1052–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Eggebrecht H, Schelle S, Puls M, et al. Risk and outcomes of complications during and after MitraClip implantation: experience in 828 patients from the German TRAnscatheter mitral valve interventions (TRAMI) registry. Catheter Cardiovasc Interv. 2015;86(4):728–35.CrossRefPubMedGoogle Scholar
  8. 8.
    Grayburn PA, Foster E, Sangli C, et al. Relationship between the magnitude of reduction in mitral regurgitation severity and left ventricular and left atrial reverse remodeling after MitraClip therapy. Circulation. 2013;128(15):1667–74.CrossRefPubMedGoogle Scholar
  9. 9.
    Adams DH, Rosenhek R, Falk V. Degenerative mitral valve regurgitation: best practice revolution. Eur Heart J. 2010;31(16):1958–66.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Dayan V, Soca G, Cura L, Mestres CA. Similar survival after mitral valve replacement or repair for ischemic mitral regurgitation: a meta-analysis. Ann Thorac Surg. 2014;97(3):758–65.CrossRefPubMedGoogle Scholar
  11. 11.
    Ambrozic J, Toplisek J, Knezevic I, Bunc M, Stajer D. Chronic ischemic mitral regurgitation—a diagnostic and therapeutic challenge. Slov Med J. 2014;83(1):54–69.Google Scholar
  12. 12.
    Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients With Functional Mitral Regurgitation (The COAPT Trial) (COAPT). Available at: https://clinicaltrials.gov/ct2/show/NCT01626079. Accessed November 10, 2017.
  13. 13.
    A Randomized Study of the MitraClip Device in Heart Failure Patients With Clinically Significant Functional Mitral Regurgitation (RESHAPE-HF). Available at: https://clinicaltrials.gov/ct2/show/NCT01772108. Accessed November 10, 2017.
  14. 14.
    Obadia JF, Armoiry X, Iung B, et al. The MITRA-FR study: design and rationale of a randomised study of percutaneous mitral valve repair compared with optimal medical management alone for severe secondary mitral regurgitation. EuroIntervention. 2015;10(11):1354-60.CrossRefPubMedGoogle Scholar
  15. 15.
    A Multicenter, Randomized, Controlled Study to Assess Mitral vAlve reconsTrucTion for advancEd Insufficiency of Functional or iscHemic ORigiN (MATTERHORN). Available at: https://clinicaltrials.gov/ct2/show/NCT02371512. Accessed November 10, 2017.
  16. 16.
    Goliasch G, Bartko PE, Pavo N, et al. Refining the prognostic impact of functional mitral regurgitation in chronic heart failure. Eur Heart J. 2017;  https://doi.org/10.1093/eurheartj/ehx402.Google Scholar
  17. 17.
    GRASP-IT Investigators, Capodanno D, Adamo M, Barbanti M, et al. Predictors of clinical outcomes after edge-to-edge percutaneous mitral valve repair. Am Heart J. 2015;170(1):187–95.CrossRefGoogle Scholar
  18. 18.
    Melisurgo G, Ajello S, Pappalardo F, et al. Afterload mismatch after MitraClip insertion for functional mitral regurgitation. Am J Cardiol. 2014;113(11):1844–50.CrossRefPubMedGoogle Scholar
  19. 19.
    Pleger ST, Chorianopoulos E, Krumsdorf U, Katus HA, Bekeredjian R. Percutaneous edge-to-edge repair of mitral regurgitation as a bail-out strategy in critically ill patients. J Invasive Cardiol. 2013;25(2):69–72.PubMedGoogle Scholar
  20. 20.
    Kreidel F, Frerker C, Schlüter M, et al. Repeat MitraClip therapy for significant recurrent mitral regurgitation in high surgical risk patients: impact of loss of leaflet insertion. JACC Cardiovasc Interv. 2015;8(11):1480–9.CrossRefPubMedGoogle Scholar
  21. 21.
    Glower DD, Kar S, Trento A, et al. Percutaneous mitral valve repair for mitral regurgitation in high-risk patients: results of the EVEREST II study. J Am Coll Cardiol. 2014;64(2):172–81.CrossRefPubMedGoogle Scholar
  22. 22.
    Kische S, Nienaber C, Ince H. Use of four MitraClip devices in a patient with ischemic cardiomyopathy and mitral regurgitation: “zipping by clipping”. Catheter Cardiovasc Interv. 2012;80(6):1007–13.CrossRefPubMedGoogle Scholar
  23. 23.
    Schaefer U, Frerker C, Kreidel F. Simultaneous double clipping delivery guide strategy for treatment of severe coaptation failure in functional mitral regurgitation. Heart Lung Circ. 2015;24(1):98–102.CrossRefPubMedGoogle Scholar
  24. 24.
    Wunderlich NC, Siegel RJ. Peri-interventional echo assessment for the MitraClip procedure. Eur Heart J Cardiovasc Imaging. 2013;14(10):935–49.CrossRefPubMedGoogle Scholar
  25. 25.
    Zeng X, Levine RA, Hua L, et al. Diagnostic value of vena contracta area in the quantification of mitral regurgitation severity by color Doppler 3D echocardiography. Circ Cardiovasc Imaging. 2011;4(5):506–13.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Hamilton-Craig C, Strugnell W, Gaikwad N, et al. Quantitation of mitral regurgitation after percutaneous MitraClip repair: comparison of Doppler echocardiography and cardiac magnetic resonance imaging. Ann Cardiothorac Surg. 2015;4(4):341–51.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Smith T, McGinty P, Bommer W, et al. Prevalence and echocardiographic features of iatrogenic atrial septal defect after catheter-based mitral valve repair with the MitraClip system. Catheter Cardiovasc Interv. 2012;80(4):678–85.CrossRefPubMedGoogle Scholar
  28. 28.
    Schueler R, Öztürk C, Wedekind JA, et al. Persistence of iatrogenic atrial septal defect after interventional mitral valve repair with theMitraClip system: a note of caution. JACC Cardiovasc Interv. 2015;8(3):450–9.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Austria, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Clinical Department of CardiologyUniversity Medical Centre LjubljanaLjubljanaSlovenia
  2. 2.Clinical Department of Anesthesiology and Perioperative Intensive TherapyUniversity Medical Centre LjubljanaLjubljanaSlovenia

Personalised recommendations